Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants.

The analyst told investors in a research note that this development is significant for Vaxcyte, Inc. (NASDAQ:PCVX), as its pneumococcal vaccine candidates contain aluminum adjuvant at levels similar to those found in Merck’s Vaxneuvance and Pfizer’s Prevnar 20.

The firm stated that aluminum adjuvants are present in several vaccines recommended by the Centers for Disease Control and Prevention for infants and children and have been used widely since the 1930s.

It added that the FDA’s work shows that aluminum exposure from vaccines is safe, and sees the “preponderance of evidence” as supporting the use of aluminum adjuvants in vaccines. Mizuho thus stated that if a review of licensed vaccines containing aluminum adjuvant is carried out, it “will prove this out.”

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.